Across STEP 1 and 3 trials involving non-diabetic participants, semaglutide 2.4 mg exhibited average placebo-adjusted weight reductions of 12.4% and 10.3%, respectively, by week 68
Follow medication instructions and direction from your doctor
This macro pattern works best: center meals on protein, fiber-rich vegetables, and moderate portions of complex carbohydrates
Weight loss injections, particularly GLP-1 receptor agonists like semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro), have revolutionized obesity management, but questions about their cardiovascular safety remain a priority for patients and clinicians
these changes may be a sign of degradation or contamination
See all FAQs Important safety information and common side effects GLP-1 medications should be used with a reduced-calorie meal plan and increased physical activity